Clinical data | |
---|---|
Trade names | Heberprot-P, Easyef, Genesoft, Kang He Su, Regen-D[1] |
Other names | Recombinant human epidermal growth factor; rhEGF; DWP-401 |
Routes of administration | intralesional injection; Topical |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.241.060 |
Chemical and physical data | |
Formula | C270H401N73O83S7 |
Molar mass | 6222.03 g·mol−1 |
3D model (JSmol) | |
| |
|
Nepidermin (INN proposed),[2] also known as recombinant human epidermal growth factor (rhEGF), is a recombinant form of human epidermal growth factor (EGF) and a cicatrizant (a drug that promotes wound healing through formation of scar tissue). As a recombinant form of EGF, nepidermin is an agonist of the epidermal growth factor receptor (EGFR), and is the first EGFR agonist to be marketed.[3][4] It was developed by Cuban Center for Genetic Engineering and Biotechnology (CIBG), and has been marketed by Heber Biotech as an intralesional injection for diabetic foot ulcer under the trade name Heberprot-P since 2006.[5][6] As of 2016, Heberprot-P had been marketed in 23 countries,[7] but remains unavailable in the United States. In 2015, preparations were made to conduct the Phase III trials required for FDA approval,[8][9] however as of 2023 developments in U.S.-Cuba relations have stymied importation of the drug from Cuba.
Various forms of rhEGF are marketed for the treatment of diabetic foot ulcers, wounds, and alopecia (hair loss) in Vietnam, the Philippines, Thailand, and China.[1][3][4]
Drugs.com
was invoked but never defined (see the help page).AdisInsight
was invoked but never defined (see the help page).LauKim2016
was invoked but never defined (see the help page).